Sotatercept as a Therapeutic Option for Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension With Features of PVOD/PCH Authors: Yujin Nishioka, Keita Imanishi, Erika Matsuda, Wataru Nakamura, Ryosuke Shirayanagi, Hiroto Ojiro, Akira Katagiri Published: 2026 ABSTRACT ABSTRACTA 53‐year‐old woman with systemic sclerosis‐associated pulmonary arterial hypertension (SSc‐PAH) presented with severe exertional desaturation, markedly reduced diffusing capacity (%DLCO 30%), and computed tomography findings demonstrating features of pulmonary veno‐occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH). Despite triple oral therapy, pulmonary hypertension progressively worsened, with mean pulmonary arterial pressure increasing from 34 to 51 mmHg. Sotatercept was initiated because of concerns about the risk of pulmonary edema with parenteral prostacyclin therapy. Despite intermittent treatment interruption due to hemoglobin elevation, improvements were observed in World Health Organization functional class (III–II), 6‐min walk distance (217–301 m), brain natriuretic peptide (206.4–52.8 pg/mL), and mean pulmonary arterial pressure (51–45 mmHg), without pulmonary edema. This case suggests a potential benefit of sotatercept in selected patients with SSc‐PAH with features of PVOD/PCH.Keywords: pulmonary arterial hypertension, pulmonary edema, systemic sclerosis Introduction Systemic sclerosis‐associated pulmonary arterial hypertension (SSc‐PAH) is a heterogeneous condition in which features of pulmonary veno‐occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) may coexist with arterial lesions [1]. Recognition of these features is clinically important because aggressive pulmonary vasodilator therapy may increase the risk of pulmonary edema [2]. The optimal treatment strategy for such mixed pulmonary vascular phenotypes remains unclear. We present a case of SSc‐PAH with features of PVOD/PCH in which sotatercept was selected as a therapeutic option. Case Presentation A 53‐year‐old woman with limited cutaneous systemic sclerosis and anticentromere antibody positivity was referred for evaluation of pulmonary hypertension. She had no smoking history, interstitial lung disease, or major comorbidities. At diagnosis, she presented with exertional dyspnea corresponding to World Health Organization (WHO) functional Class III and severe exertional desaturation during a 6‐min walk test, which could not be completed because oxygen saturation fell below 80% before 100 m of walking distance. Baseline echocardiographic and hemodynamic findings are summarized in Figure 1. Pulmonary function testing demonstrated preserved lung volume (%FVC 86%) with markedly reduced diffusing capacity (%DLCO 30%). High‐resolution computed tomography revealed diffuse centrilobular ground‐glass opacities and mediastinal lymphadenopathy without pulmonary fibrosis, suggestive of PAH with features of PVOD/PCH (Figure 1A). The patient was classified as high risk according to ESC/ERS and REVEAL 2.0 assessments. (A) High‐resolution chest CT showing diffuse centrilobular ground‐glass opacities and mediastinal lymphadenopathy suggestive of PVOD/PCH‐like features. (B) Serial changes in BNP and mPAP during the clinical course. (C) Serial clinical, functional, echocardiographic, and hemodynamic findings. 6MWD, 6‐min walk distance; BNP, brain natriuretic peptide; mPAP, mean pulmonary arterial pressure; PVR, pulmonary vascular resistance; RA, right atrium; RAP, right atrial pressure; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; TRPG, tricuspid regurgitation peak gradient; WHO, World Health Organization. Initial treatment with macitentan (10 mg/day) and tadalafil (40 mg/day) was started at diagnosis, and home oxygen therapy was introduced because of severe exertional desaturation. Selexipag was initiated 6 months later and titrated to 1.2 mg/day; however, the dose was subsequently reduced to 0.8 mg/day because of gastrointestinal adverse effects. While a transient improvement was observed during the first year, pulmonary hypertension progressively worsened approximately 18 months after diagnosis despite triple oral therapy (Figure 1B). Follow‐up hemodynamic and functional findings, including thermodilution‐derived cardiac index, are summarized in Figure 1C. Repeat computed tomography demonstrated persistent centrilobular ground‐glass opacities and mediastinal lymphadenopathy, and did not reveal pulmonary edema. However, pericardial effusion was confirmed not only by echocardiography but also by CT scans. Although a worsening of PAH was confirmed, switching to intravenous prostacyclin was considered high risk due to the risk of pulmonary edema caused by its potent vasodilatory effect. Therefore, sotatercept was initiated at 0.3 mg/kg and escalated to 0.7 mg/kg after 3 weeks. The first three administrations were completed consecutively; however, hemoglobin elevation developed after the first administration and progressively worsened after the second administration, reaching a peak hemoglobin level of 17.7 g/dL. Consequently, treatment was intermittently withheld, and only 6 of 10 planned administrations could be completed. Treatment intervals were extended up to 9 weeks. The final dose was reduced to 0.3 mg/kg, after which hemoglobin elevation became less pronounced. No clinically significant adverse events other than hemoglobin elevation, including epistaxis or headache, were observed. Despite incomplete dosing, clinical improvement was observed after sotatercept initiation, including improvements in WHO functional class (from III to II), exercise tolerance (6‐min walk distance [6MWD], from 217 to 301 m under unchanged oxygen supplementation), brain natriuretic peptide (BNP) (from 206.4 to 52.8 pg/mL), and hemodynamics (mean pulmonary arterial pressure [mPAP] decrease from 51 to 45 mmHg and cardiac index increased from 2.62 to 2.88 L/min/m2) (Figure 1C). No clinical or radiographic pulmonary edema developed during follow‐up. Discussion This case highlights the clinical importance of recognizing SSc‐PAH with features of PVOD/PCH. Although smooth interlobular septal thickening was not prominent, the combination of markedly reduced diffusing capacity, severe exertional desaturation, and characteristic computed tomography findings, including centrilobular ground‐glass opacities and mediastinal lymphadenopathy, suggested a mixed pulmonary vascular phenotype involving arterial, venous, and capillary components. Recognition of such features is clinically important because treatment strategies may differ substantially. In patients with suspected venous or capillary involvement, aggressive pulmonary vasodilation, particularly with parenteral prostacyclin therapy, may increase the risk of life‐threatening pulmonary edema. This may result from increased pulmonary blood flow in the setting of impaired post‐capillary drainage [2]. In the present case, persistent severe hypoxemia and PVOD/PCH‐like imaging findings raised concern regarding this risk. In addition, continuous intravenous prostacyclin therapy was considered undesirable because of infection concerns associated with concomitant immunosuppressive therapy [3]. Despite progressive deterioration during triple oral therapy, clinical improvement was observed following sotatercept initiation. Sotatercept was considered potentially safer because it may improve vascular remodeling without intensive vasodilation. Although hemodynamic improvement was modest, WHO functional class, BNP, exercise tolerance, and exertional symptoms improved without the development of pulmonary edema. Previous studies have also reported marked improvement in 6MWD after sotatercept therapy [4, 5]. Although 6MWD correlates only moderately with objective exercise capacity measures [6], the magnitude of improvement observed in the present case, together with improvement in WHO functional class, suggests a clinically meaningful functional benefit. Notably, these benefits were observed despite incomplete dosing caused by hemoglobin elevation. These effects may reflect early vascular improvement, consistent with experimental studies demonstrating early reversal of pulmonary vascular wall thickening in rat models of PAH [7]. These findings raise the possibility that the observed functional improvement, despite only a modest reduction in mPAP, may not be fully explained by hemodynamic changes alone. The effects of sotatercept on venous and capillary pathology remain unclear. However, limited data suggest that sotatercept may also have therapeutic potential in PAH with PVOD/PCH features [8]. Together with the present case, these observations support further investigation of sotatercept in mixed pulmonary vascular phenotypes. Several limitations should be acknowledged. First, PVOD/PCH was not histologically confirmed. Second, the observed clinical course may not be generalizable to patients with overt right heart failure or hemodynamic instability in whom intensive management—including parenteral prostacyclin—may still be required. In addition, concomitant immunosuppressive therapy may have influenced the disease course. Nevertheless, this case supports a phenotype‐guided therapeutic approach in selected SSc‐PAH with features of PVOD/PCH. Conclusion Sotatercept may represent a therapeutic option for selected patients with SSc‐PAH with features of PVOD/PCH. This case underscores the importance of phenotype‐guided treatment strategies and suggests that modulation of vascular remodeling may provide clinically meaningful benefits even in patients with only modest hemodynamic improvement. Author Contributions Y.N. and K.I. collected data and wrote the preliminary manuscript. All coauthors contributed to data collection and manuscript preparation. Funding The authors have nothing to report. Ethics Statement Written and verbal informed consent was obtained for data usage from the patient. Conflicts of Interest The authors declare no conflicts of interest. Guarantor Y.N. is the guarantor of this work. Acknowledgments We would like to thank the cardiology team for their assistance in performing and interpreting the right heart catheterization. The authors would also like to thank Editage (www.editage.com) for English language editing. Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data supporting the findings of this study are available from the corresponding author upon reasonable request.